There are 5 million Americans that suffer from Alzheimer’s disease, 1 million from Parkinson’s disease, 400,000 from multiple sclerosis, 30,000 from ALS, and 30,000 from Huntington’s disease. Neurodegenerative diseases are prevalent and devastating. Without medical advances or proper treatment, more than 12 million Americans will suffer from neurodegenerative diseases in 30 years.
Amylyx Pharmaceuticals aims to bring an innovative approach to treat neurodegenerative diseases by fostering strong partnerships with industry leaders, scientists, doctors, and organizations to positively improve the quality of life for suffering patients. With the driving goal of preventing neuronal death, Amylyx aims to be a game-changer in neurodegenerative therapeutics.
